Pneumatosis coli: A source of diagnostic confusion

1990 ◽  
Vol 77 (2) ◽  
pp. 155-155 ◽  
Author(s):  
A. D. Spigelman ◽  
C. B. Williams ◽  
J. K. Ansell ◽  
K. R. P. Rutter ◽  
R. K. S. Phillips
2011 ◽  
Vol 49 (05) ◽  
Author(s):  
L Dzirlo ◽  
E Buchinger ◽  
P Weiss

ORL ro ◽  
2016 ◽  
Vol 1 (1) ◽  
pp. 48-50
Author(s):  
Adina A. Zamfir-Chiru-Anton ◽  
D.C. Gheorghe

The authors present the case of a 4-year-old child admitted to the ENT Department with possible pulmonary foreign body aspiration. A detailed history revealed a clinical picture that seemed to depict an absence episode (with partial loss of conscience and cianosis) occured when eating, less the symptomes of a respiratory foreign body. Diagnosis needed full respiratory endoscopy and neurologic evaluation for correct assesment and effective therapy approach.


2020 ◽  
Vol 20 ◽  
Author(s):  
Nan Wang ◽  
Rui Kong ◽  
Wei Han ◽  
Jie Lu

Background: Hepatoid adenocarcinoma of the stomach (HAS) has been recognized as a rare primary gastric tumor characterized by hepatocellular carcinoma-like histology. HAS often causes diagnostic confusion with conventional gastric adenocarcinoma (CGA) due to the difficulty to detect hepatoid differentiation solely based on findings from hematoxylin and eosin (H&E) staining. Hence, HAS should be distinguished from solid-type CGA based on their different biological behaviors. β-catenin is highly expressed in hepatocellular carcinoma (HCC), which is involved in the maintenance of tumor initiating cells, drug resistance, tumor progression, and metastasis. Methods and Results: Given the dearth of HAS cases, systematic examination of the expression of β-catenin in HAS remains under-explored. In this study, 14 cases were subjected to immunostaining with with AFP, β-catenin, glypican3, hepar-1 and CerbB-2. In parallel, the clinicopathological characteristics of these patients were collected. We detected statistically significant difference in the expression of β-catenin (P = 0.000), glypican3 (P = 0.019), and hepar-1 (P = 0.007) between HAS cancer tissues and the adjacent non-cancerous tissues. Furthermore, a significant correlation was observed between the expression of β-catenin in HAS cancer tissue and adjacent tissue (Pearson correlation coefficient: 0.686, P = 0.007). Moreover, in cancer tissues, a significant correlation was observed between the expression of β-catenin and survival time (Spearman correlationcoefficient= - 0.482, P = 0.003). However, we found the expression of β-catenin did not correlate with the degree of tumor differentiation and tumor size, age, gender, serum AFP levels, microinvasion, and metastasis (P > 0.05). Conclusion: Our findings establish β-catenin as a useful marker that can distinguish HAS from CGA and may improve the early diagnosis to guide the appropriate and timely treatment of HAS patients.


1979 ◽  
Vol 97 (8) ◽  
pp. 1482-1486 ◽  
Author(s):  
W. E. Benson ◽  
J. A. Shields ◽  
W. Tasman ◽  
A. S. Crandall

1981 ◽  
Vol 137 (3) ◽  
pp. 624-625 ◽  
Author(s):  
WB Gefter ◽  
KA Evers ◽  
PF Malet ◽  
HY Kressel ◽  
JJ Thompson

2015 ◽  
Vol 21 (6) ◽  
pp. 681-682 ◽  
Author(s):  
Inês Vasconcelos ◽  
Cornelia Radke ◽  
Óscar Tellechea ◽  
Winfried Schoenegg
Keyword(s):  

2010 ◽  
Vol 3 (4) ◽  
pp. 293-300
Author(s):  
Leandro Cordero ◽  
Peter J. Giannone ◽  
Christina J. Valentine ◽  
Brian D. Coley ◽  
Craig A. Nankervis

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Hyman M. Schipper

Decreased -amyloid1-42and increased phospho-tau protein levels in the cerebrospinal fluid (CSF) are currently the most accurate chemical neurodiagnostics of sporadic Alzheimer disease (AD). A report (2007) of the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (2006) recommended that biological markers shouldnotbe currently requisitioned by primary care physicians in the routine investigation of subjects with memory complaints. Consideration for such testing should prompt patient referral to a specialist engaged in dementia evaluations or a Memory Clinic. The specialist should consider having CSF biomarkers (-amyloid1-42and phospho-tau) measured at a reputable facility in restricted cases presenting with atypical features and diagnostic confusion, but not as a routine procedure in all individuals with typical sporadic AD phenotypes. We submit that developments in the field of AD biomarker discovery since publication of the 3rd CCCDTD consensus data do not warrant revision of the 2007 recommendations.


Sign in / Sign up

Export Citation Format

Share Document